Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo studies
This study is using the targeted approach and anti-inflammatory action of the probiotic biomass to lessen the side effects of therapeutic agents of ulcerative colitis. The aim of the present study is to prepare mesalamine loaded eudragit S-100 with probiotic microparticles by spray drying method. Th...
Gespeichert in:
| Veröffentlicht in: | Drug development and industrial pharmacy 2019-11, Vol.45 (11), p.1807-1820 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1820 |
|---|---|
| container_issue | 11 |
| container_start_page | 1807 |
| container_title | Drug development and industrial pharmacy |
| container_volume | 45 |
| creator | Thakur, Vandana Singh, Amandeep Joshi, Nabin Mishra, Neeraj |
| description | This study is using the targeted approach and anti-inflammatory action of the probiotic biomass to lessen the side effects of therapeutic agents of ulcerative colitis. The aim of the present study is to prepare mesalamine loaded eudragit S-100 with probiotic microparticles by spray drying method. The in-vitro release of the optimized formulation was 90.55 ± 2.42 in 24 hr, which display controlled drug release of mesalamine at a particular region. Mesalamine loaded eudragit S-100 with probiotic microparticles (F12) presented average particle size of 4.91 µm. The statistical analysis was done by one way ANOVA and then comparison test of Bonferroni was done and p values |
| doi_str_mv | 10.1080/03639045.2019.1665059 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_03639045_2019_1665059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2286940181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-9ce944146b643e112d8892a36c9059f501704b7cb98b1947b1c70e5fc2d5bd0e3</originalsourceid><addsrcrecordid>eNp9kc2KFDEUhYMoTjv6CEqWbqpNUklV4koZ_IMBF-q6yM8tJpJU2iTVQz-DLz0puselq8uF75zLPQeh15TsKZHkHemHXhEu9oxQtafDIIhQT9COCkY6MQ7sKdptTLdBV-hFKb8JoUwJ8Rxd9ZRLJZnaob8_DlmfsMseHJ5TjmvQ1acFpxlHKDro6BfAEA0415B7X-_wISfjU_UWtxF1KZsS1zvANYOuEZa66ddgITe3I2Cbgq--vMd-6Y6-5oT14s7LMeFSV-ehvETPZh0KvLrMa_Tr86efN1-72-9fvt18vO0sk7R2yoLinPLBDLwHSpmTUjHdD1a1CGZB6Ei4Ga1R0lDFR0PtSEDMljlhHIH-Gr09-7Y__qxQ6hR9sRCCXiCtZWJMDooTKmlDxRm1OZWSYZ4O2UedTxMl09bD9NjDtPUwXXpoujeXE6uJ4P6pHoNvwIcz4JctdX2fcnBT1aeQ8pz1Yn1p8H9vPAAnoJmL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2286940181</pqid></control><display><type>article</type><title>Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo studies</title><source>MEDLINE</source><source>EBSCOhost Business Source Complete</source><creator>Thakur, Vandana ; Singh, Amandeep ; Joshi, Nabin ; Mishra, Neeraj</creator><creatorcontrib>Thakur, Vandana ; Singh, Amandeep ; Joshi, Nabin ; Mishra, Neeraj</creatorcontrib><description>This study is using the targeted approach and anti-inflammatory action of the probiotic biomass to lessen the side effects of therapeutic agents of ulcerative colitis. The aim of the present study is to prepare mesalamine loaded eudragit S-100 with probiotic microparticles by spray drying method. The in-vitro release of the optimized formulation was 90.55 ± 2.42 in 24 hr, which display controlled drug release of mesalamine at a particular region. Mesalamine loaded eudragit S-100 with probiotic microparticles (F12) presented average particle size of 4.91 µm. The statistical analysis was done by one way ANOVA and then comparison test of Bonferroni was done and p values <.05 were considered as significant. The effects of spray dried microparticles over inflamed Caco-2 cell were also evaluated by determining the concentration of IL-8. From in-vivo study it was seen that pretreatment of mesalamine with probiotic prevents DNBS (Dinitrobenzenesulfonic acid) induced colitis in rats and represents protective action against ulcerative colitis because of its antioxidant and anti-inflammatory actions. The results give the foundation for a combination of targeted approach along with the anti-inflammatory potential of the probiotic which might help to decrease the problems which are seen with the traditional cure and management of ulcerative colitis.</description><identifier>ISSN: 0363-9045</identifier><identifier>EISSN: 1520-5762</identifier><identifier>DOI: 10.1080/03639045.2019.1665059</identifier><identifier>PMID: 31489829</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics ; Benzenesulfonates - toxicity ; Caco-2 Cells ; Colitis, Ulcerative - chemically induced ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - pathology ; Colon - drug effects ; Colon - pathology ; Disease Models, Animal ; DNBS ; Drug Carriers - chemistry ; Drug Combinations ; Drug Compounding - methods ; Drug Liberation ; Female ; Humans ; Lactobacillus acidophilus ; Male ; mesalamine ; Mesalamine - administration & dosage ; Mesalamine - adverse effects ; Mesalamine - pharmacokinetics ; Particle Size ; Polymethacrylic Acids - chemistry ; probiotic (L. acidophilus spores) ; Probiotics - administration & dosage ; Probiotics - pharmacokinetics ; Rats ; Rats, Wistar ; spray drying ; Ulcerative colitis</subject><ispartof>Drug development and industrial pharmacy, 2019-11, Vol.45 (11), p.1807-1820</ispartof><rights>2019 Informa UK Limited, trading as Taylor & Francis Group 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c281t-9ce944146b643e112d8892a36c9059f501704b7cb98b1947b1c70e5fc2d5bd0e3</citedby><cites>FETCH-LOGICAL-c281t-9ce944146b643e112d8892a36c9059f501704b7cb98b1947b1c70e5fc2d5bd0e3</cites><orcidid>0000-0003-1994-1487 ; 0000-0002-4077-5711 ; 0000-0002-3711-0452 ; 0000-0001-9127-4469</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31489829$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thakur, Vandana</creatorcontrib><creatorcontrib>Singh, Amandeep</creatorcontrib><creatorcontrib>Joshi, Nabin</creatorcontrib><creatorcontrib>Mishra, Neeraj</creatorcontrib><title>Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo studies</title><title>Drug development and industrial pharmacy</title><addtitle>Drug Dev Ind Pharm</addtitle><description>This study is using the targeted approach and anti-inflammatory action of the probiotic biomass to lessen the side effects of therapeutic agents of ulcerative colitis. The aim of the present study is to prepare mesalamine loaded eudragit S-100 with probiotic microparticles by spray drying method. The in-vitro release of the optimized formulation was 90.55 ± 2.42 in 24 hr, which display controlled drug release of mesalamine at a particular region. Mesalamine loaded eudragit S-100 with probiotic microparticles (F12) presented average particle size of 4.91 µm. The statistical analysis was done by one way ANOVA and then comparison test of Bonferroni was done and p values <.05 were considered as significant. The effects of spray dried microparticles over inflamed Caco-2 cell were also evaluated by determining the concentration of IL-8. From in-vivo study it was seen that pretreatment of mesalamine with probiotic prevents DNBS (Dinitrobenzenesulfonic acid) induced colitis in rats and represents protective action against ulcerative colitis because of its antioxidant and anti-inflammatory actions. The results give the foundation for a combination of targeted approach along with the anti-inflammatory potential of the probiotic which might help to decrease the problems which are seen with the traditional cure and management of ulcerative colitis.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics</subject><subject>Benzenesulfonates - toxicity</subject><subject>Caco-2 Cells</subject><subject>Colitis, Ulcerative - chemically induced</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Colon - drug effects</subject><subject>Colon - pathology</subject><subject>Disease Models, Animal</subject><subject>DNBS</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Combinations</subject><subject>Drug Compounding - methods</subject><subject>Drug Liberation</subject><subject>Female</subject><subject>Humans</subject><subject>Lactobacillus acidophilus</subject><subject>Male</subject><subject>mesalamine</subject><subject>Mesalamine - administration & dosage</subject><subject>Mesalamine - adverse effects</subject><subject>Mesalamine - pharmacokinetics</subject><subject>Particle Size</subject><subject>Polymethacrylic Acids - chemistry</subject><subject>probiotic (L. acidophilus spores)</subject><subject>Probiotics - administration & dosage</subject><subject>Probiotics - pharmacokinetics</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>spray drying</subject><subject>Ulcerative colitis</subject><issn>0363-9045</issn><issn>1520-5762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2KFDEUhYMoTjv6CEqWbqpNUklV4koZ_IMBF-q6yM8tJpJU2iTVQz-DLz0puselq8uF75zLPQeh15TsKZHkHemHXhEu9oxQtafDIIhQT9COCkY6MQ7sKdptTLdBV-hFKb8JoUwJ8Rxd9ZRLJZnaob8_DlmfsMseHJ5TjmvQ1acFpxlHKDro6BfAEA0415B7X-_wISfjU_UWtxF1KZsS1zvANYOuEZa66ddgITe3I2Cbgq--vMd-6Y6-5oT14s7LMeFSV-ehvETPZh0KvLrMa_Tr86efN1-72-9fvt18vO0sk7R2yoLinPLBDLwHSpmTUjHdD1a1CGZB6Ei4Ga1R0lDFR0PtSEDMljlhHIH-Gr09-7Y__qxQ6hR9sRCCXiCtZWJMDooTKmlDxRm1OZWSYZ4O2UedTxMl09bD9NjDtPUwXXpoujeXE6uJ4P6pHoNvwIcz4JctdX2fcnBT1aeQ8pz1Yn1p8H9vPAAnoJmL</recordid><startdate>20191102</startdate><enddate>20191102</enddate><creator>Thakur, Vandana</creator><creator>Singh, Amandeep</creator><creator>Joshi, Nabin</creator><creator>Mishra, Neeraj</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1994-1487</orcidid><orcidid>https://orcid.org/0000-0002-4077-5711</orcidid><orcidid>https://orcid.org/0000-0002-3711-0452</orcidid><orcidid>https://orcid.org/0000-0001-9127-4469</orcidid></search><sort><creationdate>20191102</creationdate><title>Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo studies</title><author>Thakur, Vandana ; Singh, Amandeep ; Joshi, Nabin ; Mishra, Neeraj</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-9ce944146b643e112d8892a36c9059f501704b7cb98b1947b1c70e5fc2d5bd0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics</topic><topic>Benzenesulfonates - toxicity</topic><topic>Caco-2 Cells</topic><topic>Colitis, Ulcerative - chemically induced</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Colon - drug effects</topic><topic>Colon - pathology</topic><topic>Disease Models, Animal</topic><topic>DNBS</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Combinations</topic><topic>Drug Compounding - methods</topic><topic>Drug Liberation</topic><topic>Female</topic><topic>Humans</topic><topic>Lactobacillus acidophilus</topic><topic>Male</topic><topic>mesalamine</topic><topic>Mesalamine - administration & dosage</topic><topic>Mesalamine - adverse effects</topic><topic>Mesalamine - pharmacokinetics</topic><topic>Particle Size</topic><topic>Polymethacrylic Acids - chemistry</topic><topic>probiotic (L. acidophilus spores)</topic><topic>Probiotics - administration & dosage</topic><topic>Probiotics - pharmacokinetics</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>spray drying</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thakur, Vandana</creatorcontrib><creatorcontrib>Singh, Amandeep</creatorcontrib><creatorcontrib>Joshi, Nabin</creatorcontrib><creatorcontrib>Mishra, Neeraj</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug development and industrial pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thakur, Vandana</au><au>Singh, Amandeep</au><au>Joshi, Nabin</au><au>Mishra, Neeraj</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo studies</atitle><jtitle>Drug development and industrial pharmacy</jtitle><addtitle>Drug Dev Ind Pharm</addtitle><date>2019-11-02</date><risdate>2019</risdate><volume>45</volume><issue>11</issue><spage>1807</spage><epage>1820</epage><pages>1807-1820</pages><issn>0363-9045</issn><eissn>1520-5762</eissn><abstract>This study is using the targeted approach and anti-inflammatory action of the probiotic biomass to lessen the side effects of therapeutic agents of ulcerative colitis. The aim of the present study is to prepare mesalamine loaded eudragit S-100 with probiotic microparticles by spray drying method. The in-vitro release of the optimized formulation was 90.55 ± 2.42 in 24 hr, which display controlled drug release of mesalamine at a particular region. Mesalamine loaded eudragit S-100 with probiotic microparticles (F12) presented average particle size of 4.91 µm. The statistical analysis was done by one way ANOVA and then comparison test of Bonferroni was done and p values <.05 were considered as significant. The effects of spray dried microparticles over inflamed Caco-2 cell were also evaluated by determining the concentration of IL-8. From in-vivo study it was seen that pretreatment of mesalamine with probiotic prevents DNBS (Dinitrobenzenesulfonic acid) induced colitis in rats and represents protective action against ulcerative colitis because of its antioxidant and anti-inflammatory actions. The results give the foundation for a combination of targeted approach along with the anti-inflammatory potential of the probiotic which might help to decrease the problems which are seen with the traditional cure and management of ulcerative colitis.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>31489829</pmid><doi>10.1080/03639045.2019.1665059</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-1994-1487</orcidid><orcidid>https://orcid.org/0000-0002-4077-5711</orcidid><orcidid>https://orcid.org/0000-0002-3711-0452</orcidid><orcidid>https://orcid.org/0000-0001-9127-4469</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-9045 |
| ispartof | Drug development and industrial pharmacy, 2019-11, Vol.45 (11), p.1807-1820 |
| issn | 0363-9045 1520-5762 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_03639045_2019_1665059 |
| source | MEDLINE; EBSCOhost Business Source Complete |
| subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics Benzenesulfonates - toxicity Caco-2 Cells Colitis, Ulcerative - chemically induced Colitis, Ulcerative - drug therapy Colitis, Ulcerative - pathology Colon - drug effects Colon - pathology Disease Models, Animal DNBS Drug Carriers - chemistry Drug Combinations Drug Compounding - methods Drug Liberation Female Humans Lactobacillus acidophilus Male mesalamine Mesalamine - administration & dosage Mesalamine - adverse effects Mesalamine - pharmacokinetics Particle Size Polymethacrylic Acids - chemistry probiotic (L. acidophilus spores) Probiotics - administration & dosage Probiotics - pharmacokinetics Rats Rats, Wistar spray drying Ulcerative colitis |
| title | Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A26%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spray%20dried%20formulation%20of%20mesalamine%20embedded%20with%20probiotic%20biomass%20for%20the%20treatment%20of%20ulcerative%20colitis:%20in-vitro%20and%20in-vivo%20studies&rft.jtitle=Drug%20development%20and%20industrial%20pharmacy&rft.au=Thakur,%20Vandana&rft.date=2019-11-02&rft.volume=45&rft.issue=11&rft.spage=1807&rft.epage=1820&rft.pages=1807-1820&rft.issn=0363-9045&rft.eissn=1520-5762&rft_id=info:doi/10.1080/03639045.2019.1665059&rft_dat=%3Cproquest_cross%3E2286940181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2286940181&rft_id=info:pmid/31489829&rfr_iscdi=true |